X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
NRX-101 (D-cycloserine & Lurasidone HCl) shows no measurable damage to either intestinal or vaginal flora, compared to the significant negative effect caused by drugs, in rodent model having complicated urinary tract infections associated with pseudomembranous colitis and vaginal yeast infections.
Lead Product(s): Cycloserine,Lurasidone Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: NRX-101
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2024
Details:
NRX-101 is a fixed dose combination of the NMDA antagonist D-cycloserine and lurasidone. It is being evaluated in phase 2/3 clinical trials for the treatment of treatment resistant bipolar depression & suicidal ideation.
Lead Product(s): Cycloserine,Lurasidone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: NRX-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2024
Details:
The collaborations aim to support NRx for the development of NRX-101 (D-cycloserine) in the treatment of bipolar depression with suicidality.
Lead Product(s): Cycloserine,Lurasidone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: NRX-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alvogen
Deal Size: $345.0 million Upfront Cash: $10.0 million
Deal Type: Collaboration February 11, 2024
Details:
NRX-101 is a fixed dose combination of the NMDA antagonist D-cycloserine and lurasidone. It is being evaluated in phase 2/3 clinical trials for the treatment of treatment resistant bipolar depression & suicidal ideation.
Lead Product(s): Cycloserine,Lurasidone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: NRX-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2024
Details:
NRX-101 (a fixed dose combination of D-cycloserine (DCS) and lurasidone HCl (lurasidone)) is an active antibiotic ingredient, NMDA receptor modulator which is under phase 2 clinical development for the treatment of complicated urinary tract infection and pyelonephritis.
Lead Product(s): Cycloserine,Lurasidone Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: NRX-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2024
Details:
NRX-101 is an oral, fixed-dose combination of D-cycloserine and lurasidone, targets the brain's N-methyl-D-aspartate (NMDA) receptor. It is being evaluated for the treatment of complicated Urinary Tract Infections.
Lead Product(s): Cycloserine,Lurasidone Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: NRX-101
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
NRX-101, an oral, fixed-dose combination of D-cycloserine and lurasidone, targets the brain's N-methyl-D-aspartate (NMDA) receptor and is being investigated for Chronic Pain.
Lead Product(s): Cycloserine,Lurasidone Hydrochloride
Therapeutic Area: Neurology Product Name: NRX-101
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2023
Details:
NRX-101, a fixed dose combination of D-cycloserine and lurasidone, product is being developed in chronic pain and post-traumatic stress disorder with depression and suicidality.
Lead Product(s): Cycloserine,Lurasidone Hydrochloride
Therapeutic Area: Neurology Product Name: NRX-101
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2023
Details:
NRX-101, a fixed dose combination of D-cycloserine and lurasidone, product is being developed in chronic pain and post-traumatic stress disorder with depression and suicidality.
Lead Product(s): Cycloserine,Lurasidone Hydrochloride
Therapeutic Area: Neurology Product Name: NRX-101
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2023
Details:
The company intends to use the net proceeds to initiate research into the use of NRX-101, an oral, fixed-dose combination of D-cycloserine and lurasidone, targets the brain's N-methyl-D-aspartate (NMDA) receptor for the treatment of PTSD and Chronic Pain.
Lead Product(s): Cycloserine,Lurasidone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: NRX-101
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $6.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 09, 2023
Details:
The collaboration aims to develop and commercialize NRX-101, an fixed dose oral combination of D-cycloserine and lurasidone for treatment-resistant suicidal bipolar depression (S-TRBD). It is one of the first oral antidepressants targeting the NMDA receptor in the brain.
Lead Product(s): Cycloserine,Lurasidone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: NRX-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Lotus Pharmaceuticals
Deal Size: $345.0 million Upfront Cash: $10.0 million
Deal Type: Collaboration June 07, 2023
Details:
Lurasidone hydrochloride is an atypical antipsychotic that is a D2 and 5-HT2A (mixed serotonin and dopamine activity) to improve cognition. It improves negative symptoms of psychoses and reduce the extrapyramidal side effects associated with typical antipsychotics.
Lead Product(s): Lurasidone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Lurasidone Hydrochloride-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2023
Details:
Lurasidone hydrochloride is a, oral atypical antipsychotic, full antagonist at dopamine D2 and serotonin 5-HT2A and 5-HT7 receptors, it is a first-line treatment option for the management of schizophrenia in adults and adolescents.
Lead Product(s): Lurasidone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Lurasidone-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2023
Details:
NRX-101 is a patented, oral fixed-dose combination of D-cycloserine (NMDA receptor modulator) and Lurasidone (5-HT2a receptor antagonist). Drug has been granted Breakthrough Therapy Designation for severe bipolar depression treatment with acute suicidal ideation or behavior.
Lead Product(s): Cycloserine,Lurasidone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: NRX-101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2023
Details:
NRX-101 is a patented, oral, fixed dose combination of D-cycloserine and lurasidone. It is the first oral drug to target suicidal bipolar depression, a significant unmet medical need, as it is estimated that approximately 50% of the 7 million individuals with bipolar disorder.
Lead Product(s): Cycloserine,Lurasidone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: NRX-101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2022
Details:
NRx Pharmaceuticals intends to use the net proceeds to support its NRX-101 (D-cycloserine) development programs for the treatment of suicidal bipolar depression and PTSD.
Lead Product(s): Cycloserine,Lurasidone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: NRX-101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Streeterville Capital
Deal Size: $11.0 million Upfront Cash: Undisclosed
Deal Type: Financing November 07, 2022
Details:
The proceeds of this investment will be targeted towards accelerating the forward path of the company's CNS/psychiatry franchise, which includes Cyclurad, and COVID vaccine franchises, together with supporting the transition of ZYESAMI from clinical to commercial stage.
Lead Product(s): Cycloserine,Lurasidone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Cyclurad
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $30.1 million Upfront Cash: Undisclosed
Deal Type: Private Placement August 19, 2021
Details:
NRx will deploy public capital to continue development of two investigational drugs: ZYESAMI™, (Aviptadil acetate) for critical Covid-19 patients with respiratory failure, and NRX-101 (D-cycloserine and lurasidone combo) for suicidal bipolar depression.
Lead Product(s): Cycloserine,Lurasidone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Cyclurad
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: NRx Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger May 25, 2021
Details:
Latuda becomes the first 2nd generation antipsychotic to be approved for patients suffering from schizophrenia as young as 13 years of age. In addition to the new indication, Latuda was also granted an additional year of marketing protection.
Lead Product(s): Lurasidone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Latuda
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sunovion Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 12, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
